Pharmacogenomic markers of metoprolol and α-OH-metoprolol concentrations: a genome-wide association study
Jean Laverdière1,2,3, Maxime Meloche1,2,3, Sylvie Provost2,3
1Faculty of Pharmacy, Université de Montréal, H3T 1J4, Montreal, Quebec, Canada.
Abstract:
Aim: Few genome-wide association studies (GWASs) have been conducted to identify predictors of drug concentrations. The authors therefore sought to discover the pharmacogenomic markers involved in metoprolol pharmacokinetics. Patients & methods: The authors performed a GWAS of a cross-sectional study of 993 patients from the Montreal Heart Institute Biobank taking metoprolol. Results: A total of 391 and 444 SNPs reached the significance threshold of 5 × 10-8 for metoprolol and α-OH-metoprolol concentrations, respectively. All were located on chromosome 22 at or near the CYP2D6 gene, encoding CYP450 2D6, metoprolol's main metabolizing enzyme. Conclusion: The results reinforce previous findings of the importance of the CYP2D6 locus for metoprolol concentrations and confirm that large biobanks can be used to identify genetic determinants of drug pharmacokinetics at a GWAS significance level.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Analysis of Population Pharmacokinetic Data
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...


